Investigate and develop new medicines more and more precise and effective, facilitate the access of patients to these innovative drugs in an environment of sustainability of the health system and to attract the country the maximum possible investment in biomedical R & D are the three main objectives of the pharmaceutical industry based in Spain.
This was stated by the president of Farmaindustria, Martin Sellés, during his speech at the First Health Forum of the newspaper El Economista, which was held this Wednesday in Madrid. In any case, “our first and main responsibility – he pointed out – is to develop innovative medicines that can cure diseases that today have no remedy or, at least, control them and ensure that patients have a good quality of life.”
Sellés stressed that, to achieve this goal, the pharmaceutical industry invests some 130,000 million euros worldwide each year, which is dedicated to basic and clinical research, an investment that makes available to doctors and patients about 40 -45 new medications per year.
In Distefar we echo the words of the president of Farmaindustria in the First Health Forum of El Economista newspaper.